Fresh Tracks Therapeutics, Inc.
NASDAQ Capital MarketTotal Valuation
Fresh Tracks Therapeutics, Inc. carries a market capitalization of 5.59M, placing it among publicly traded companies globally. Its enterprise value stands at -6.30M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 5.59M |
| Enterprise Value | -6.30M |
Share Statistics
Fresh Tracks Therapeutics, Inc. currently has 5.97M shares outstanding.
| Shares Outstanding | 5.97M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.57, and the price-to-book ratio stands at -0.03.
| PE Ratio | N/A |
| PS Ratio | 0.57 |
| PB Ratio | -0.03 |
| P/TBV Ratio | 0.46 |
| P/FCF Ratio | -1.05 |
| P/OCF Ratio | -1.05 |
Financial Position
Fresh Tracks Therapeutics, Inc. maintains a current ratio of 6.98, meaning it holds 7.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 6.98 |
| Quick Ratio | 6.59 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -1,263.80 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -52.10 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 5.39 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Fresh Tracks Therapeutics, Inc.'s stock has gained approximately 3.87735% over the past 52 weeks. The 50-day moving average sits at 0.81, while the 200-day moving average is 0.81.
| Beta (5Y) | N/A |
| 52-Week Price Change | 3.87735% |
| 50-Day Moving Average | 0.81 |
| 200-Day Moving Average | 0.81 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Fresh Tracks Therapeutics, Inc. generated 8.01M in revenue and converted that into -5.69M in net income, yielding earnings per share of -1.10. EBITDA reached -6.32M, while operating income came in at -6.36M.
| Revenue | 8.01M |
| Gross Profit | N/A |
| Operating Income | -6.36M |
| Pretax Income | -5.69M |
| Net Income | -5.69M |
| EBITDA | -6.32M |
| EBIT | -6.36M |
| Earnings Per Share (EPS) | -1.10 |
Balance Sheet
Total book value stands at -172.10M, with working capital of 9.90M providing operational flexibility.
| Cash & Cash Equivalents | 10.87M |
| Total Debt | N/A |
| Net Debt | -10.87M |
| Equity (Book Value) | -172.10M |
| Book Value Per Share | -33.15 |
| Working Capital | 9.90M |
Cash Flow
Fresh Tracks Therapeutics, Inc. produced -4.34M in operating cash flow over the past twelve months.
| Operating Cash Flow | -4.34M |
| Capital Expenditures | N/A |
| Free Cash Flow | -4.34M |
| FCF Per Share | -0.84 |
Margins
Fresh Tracks Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -79.44 and net profit margin of -71.12 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -79.44 |
| Pretax Margin | -71.12 |
| Profit Margin | -71.12 |
| EBITDA Margin | -78.93 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -143.09 |
| FCF Yield | -95.15 |
Stock Splits
Fresh Tracks Therapeutics, Inc.'s most recent stock split took place on July 5, 2022 with a 45:1 split ratio.
| Last Split Date | 7/5/2022 |
| Split Ratio | 45:1 |
Scores
Fresh Tracks Therapeutics, Inc. posts an Altman Z-Score of -19.25, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -19.25 |